Menu
Curie Logo
Donate
  • Home

Clinical trials - page 2

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Paris
    CINNAMON
    Evaluation of the quality of life induced by the anti-odor cinnamon dressing in patients with malodorous wounds: a multicenter randomized controlled trial.

  • Paris
    CLEVER-PEPTIDE (IC 2018-06)
    Open-label, non-controlled, multicenter, dose escalation, first-in-human phase I clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer.

    CHRISTOPHE LE TOURNEAU

  • Lung cancer
    Paris
    COCOON
    A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard;dermatologic management on selected dermatologic adverse events among patients with locally;advanced or metastatic EGFR-mutated NSCLC treated first-line with;amivantamab + lazertinib.

    NICOLAS GIRARD

  • Saint-Cloud
    CONTESSA - ODO-TE-B301
    Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

    ETIENNE BRAIN

  • Childhood and adolescent cancers
    Paris
    CRISP (IC 2017-08 / ITCC 053)
    A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies.

    ISABELLE AERTS GAJDOS

  • Breast cancer
    Saint-Cloud
    CT7001_003 (SUMIT ELA)
    A Phase 1b/2 Open-label Study of Samuraciclib in Combination with Elacestrant in;Participants with Metastatic or Locally Advanced Hormone Receptor-positive and Human;Epidermal Growth Factor Receptor 2-negative Breast Cancer.

    FRANCOIS-CLEMENT BIDARD

  • Lung cancer
    Paris
    CodeBreak202
    A Phase 3, Multicenter, Randomized, Open-label;Study Evaluating Efficacy of Sotorasib Platinum;Doublet Combination Versus Pembrolizumab;Platinum Doublet Combination as a Front-Line;Therapy in Subjects With Stage IV or Advanced;Stage IIIB/C Nonsquamous NonÀSmall Cell Lung;Cancers, Negative for PD-L1, and Positive for;KRAS p.G12C (CodeBreaK 202)

    NICOLAS GIRARD

  • Saint-Cloud
    DOLAF
    An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib

  • Paris
    DS 73001-003
    A PHASE 2, MULTICENTER, RANDOMIZED, OPENLABEL;STUDY OF DS-7300A, A B7-H3 ANTIBODY;DRUG CONJUGATE (ADC), IN SUBJECTS WITH;PRETREATED EXTENSIVE-STAGE SMALL CELL;LUNG CANCER (ES-SCLC).

    PAULINE DU RUSQUEC

  • Saint-Cloud
    DS8201-A-U207 DESTINY CRC02
    A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)

  • Saint-Cloud
    EMBER-2 (J2J-MC-JZLB)
    EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

    FRANCOIS-CLEMENT BIDARD

  • Paris, Saint-Cloud
    EMBER-3 (J2J-OX-JZLC)
    EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy

    FRANCOIS-CLEMENT BIDARD

  • Lung cancer
    Paris
    ENCO-BRAF (IFCT-1904)
    A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer

    CLEMENCE BASSE

  • Saint-Cloud
    EPIC 1511
    Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial.

    ELISABETH LUCCHI

  • Saint-Cloud
    EPITOP 01
    Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial

    MICHAEL BRINGUIER

  • Saint-Cloud
    ER-One (IC 2020-04)
    A Double-blind Randomized Non-inferiority Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery: Effects on Acute Postoperative Pain.

    ALINE ALBI-FELDZER

  • Saint-Cloud
    Epi R-CHOP
    A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP

    CLEMENTINE SARKOZY

  • Breast cancer
    Saint-Cloud
    FAP-IT
    68Ga-FAPI-46 PET/CT for predicting histological response;to neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

  • Saint-Cloud
    FAST
    French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study

    SANDRA MALAK

  • Saint-Cloud
    FIGARO
    Feasibility and Accuracy of Lymph-node (LN) Restaging by Sentinel LN Procedure and Axillary LN Dissection in Ipsilateral Invasive Breast Cancer Relapse

  • Saint-Cloud
    FORWARD-1
    FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

    ANNE DONNADIEU

  • Breast cancer
    Paris, Saint-Cloud
    Flamingo-01
    A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01).

    FRANCOIS-CLEMENT BIDARD

  • Saint-Cloud
    GANEA 3
    Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma.

    EUGENIE GUILLOT

  • Saint-Cloud
    GATA
    A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas

    CAROLE SOUSSAIN

  • Paris
    GCT1047-01
    First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors.

    CHRISTOPHE LE TOURNEAU

  • Kidney cancer
    Paris
    GETUG-StORM-01
    A Randomized Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases.

    GILLES CREHANGE

  • Lymphoma
    Saint-Cloud
    GO43878(GLOBRYTE)
    A PHASE III, OPEN-LABEL, MULTICENTER,;RANDOMIZED STUDY EVALUATING GLOFITAMAB AS;A SINGLE AGENT VERSUS INVESTIGATORÀS CHOICE;IN PATIENTS WITH RELAPSED/REFRACTORY;MANTLE CELL LYMPHOMA.

    CLEMENTINE SARKOZY

  • Childhood and adolescent cancers
    Paris
    GSK213406
    A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of;Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours

    FRANCOIS DOZ

  • Cervical cancer
    Saint-Cloud
    GYNET
    A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.

    DIANA BELLO ROUFAI

  • ENT/Head and Neck Cancers
    Paris
    HPV.DCVax
    Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a;therapeutic anti-HPV DC targeting vaccine in patients with Human papillomavirus;(HPV)-positive oropharyngeal cancer.

    CHRISTOPHE LE TOURNEAU

<
1 2...7
>